+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lurasidone Hydrochloride Generics Market by Application (Bipolar Depression, Major Depressive Disorder, Schizophrenia), Form (Orally Disintegrating Tablet, Tablet), Strength, Distribution Channel, End User, Packaging Type - Global Forecast 2025-2030- Product Image
Lurasidone Hydrochloride Generics Market by Application (Bipolar Depression, Major Depressive Disorder, Schizophrenia), Form (Orally Disintegrating Tablet, Tablet), Strength, Distribution Channel, End User, Packaging Type - Global Forecast 2025-2030- Product Image
New

Lurasidone Hydrochloride Generics Market by Application (Bipolar Depression, Major Depressive Disorder, Schizophrenia), Form (Orally Disintegrating Tablet, Tablet), Strength, Distribution Channel, End User, Packaging Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6125707
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The expiration of core patents on branded lurasidone hydrochloride has catalyzed a paradigm shift toward generic alternatives, creating new avenues for affordability and patient access. As health systems worldwide grapple with cost containment pressures, the introduction of high-quality generic formulations offers clinicians a broader toolkit for managing severe mood disorders. Beyond cost savings, these generics harness established safety and efficacy profiles, enabling smoother transitions in treatment protocols. This transformation underscores the importance of rigorous analytical frameworks that dissect regulatory pathways, manufacturing hurdles, and clinical adoption trends.

Building on this foundation, the subsequent analysis delves into the fundamental drivers reshaping the generic lurasidone hydrochloride landscape. We chart influential forces-from policy shifts to supply chain realignments-while illuminating how emerging stakeholders can capitalize on evolving market dynamics. Through a blend of strategic insights and empirical observations, this report equips decision-makers with the knowledge required to navigate the complexities of generic development and distribution in psychopharmacology.

Exploring the paradigm shifts reshaping the global development, regulation, and accessibility of generic lurasidone hydrochloride across healthcare systems

Over the past decade, patent cliffs and evolving regulatory frameworks have triggered transformative shifts in how generic versions of lurasidone hydrochloride are developed and approved. Agencies have streamlined bioequivalence requirements without compromising safety, allowing manufacturers to accelerate time to market. Concurrently, health technology assessments increasingly emphasize real-world evidence, prompting generic sponsors to invest in post-launch studies that validate therapeutic outcomes under routine clinical conditions.

On the distribution front, digital platforms have redefined patient engagement, enabling home delivery and telepharmacy services that expand reach beyond traditional retail channels. This proliferation of non-traditional access points has enhanced convenience for both prescribers and patients, fostering higher adherence rates and better continuity of care. Together, these regulatory and logistical evolutions are dismantling entry barriers, creating a competitive environment in which cost efficiency and clinical differentiation coexist to drive generic lurasidone hydrochloride adoption.

Assessing the cumulative impact of United States tariff adjustments in 2025 on supply chain and cost dynamics for generic lurasidone hydrochloride

The introduction of revised tariff structures in the United States during 2025 has imposed new cost considerations across the generic pharmaceutical supply chain. While modest in headline value, these adjustments amplify the importance of localized manufacturing and strategic sourcing partnerships to mitigate incremental duties on active pharmaceutical ingredients and finished dosage forms. Companies must now reconcile the balance between offshore production savings and onshore tariff liabilities.

To address these cost pressures, leading manufacturers are reassessing their supplier networks, exploring near-shore options, and leveraging trade-compliant distribution hubs. By adopting a multi-tiered sourcing strategy and aggressively negotiating long-term supply agreements, stakeholders can preserve margin stability. Moreover, proactive engagement with customs authorities and early classification of lurasidone hydrochloride formulations can expedite clearance processes, reducing inventory carrying costs and ensuring uninterrupted patient access.

Deriving nuanced segmentation insights across multiple application areas, delivery forms, dosage strengths, distribution channels, end users, and packaging formats

A nuanced understanding of how lurasidone hydrochloride generics perform across diverse applications reveals critical patterns. Within bipolar depression, patients often require tailored dosing regimens, whereas individuals with major depressive disorder gravitate toward formulations that balance efficacy with tolerability. Meanwhile, schizophrenia treatment protocols demand sustained plasma concentrations, highlighting the value of specific dosage strengths in optimizing therapeutic windows.

Formulation choices further influence adherence and patient satisfaction. Orally disintegrating tablets, for example, have gained traction in settings where rapid onset and ease of administration are paramount, contrasted against conventional tablets that offer manufacturing simplicity and cost benefits. Strength options spanning 20 mg through 80 mg enable clinicians to titrate with precision, reducing the risk of under-dosage or adverse events.

Distribution channels play a pivotal role in market reach. Hospital pharmacies, whether within general wards or psychiatric units, often serve as the first point of dispensing, while retail and online pharmacies extend continuity of care into community and home environments. Proprietary and third-party platforms alike facilitate expanded access, complementing chain and independent outlets that cater to diverse patient segments. End users in clinics, home care settings, and hospitals each present unique adoption drivers, from caregiver administration in self-management scenarios to structured dosing in acute inpatient units.

Packaging format choices, whether blister packs or bottles, further reflect stakeholder priorities around stability, dosage tracking, and cost efficiency. By weaving these segmentation layers together, industry participants can craft differentiated strategies that resonate across the therapeutic value chain.

Uncovering critical regional dynamics within Americas, Europe Middle East and Africa, and Asia Pacific shaping access to lurasidone hydrochloride generics

Regional dynamics exert a profound influence on the availability and utilization of generic lurasidone hydrochloride. In the Americas, robust generic substitution frameworks and competitive tendering have driven widespread adoption, though payer restrictions and state-level reimbursement policies can introduce variability in access. Manufacturers often tailor launch strategies to navigate these fragmented coverage landscapes and secure formulary positioning.

Across Europe, Middle East, and Africa, divergent regulatory regimes and procurement processes define the generics ecosystem. Markets with centralized tender models emphasize price competitiveness, while regions with fragmented private reimbursement recognize quality differentiation and patient support services as pivotal to uptake. Local manufacturing partnerships and technology transfer agreements frequently underpin efforts to satisfy national content requirements and reduce supply chain vulnerabilities.

In Asia Pacific, rising healthcare expenditure and expanding insurance coverage are accelerating generic penetration. Governments in key markets incentivize local production, stimulating capacity expansions among established and emerging manufacturers. Patient awareness campaigns and digital formularies further drive prescribing shifts toward cost-effective generics. However, residual concerns around quality perceptions continue to shape brand loyalty among certain prescriber cohorts.

Spotlighting leading players and competitive maneuvers within the generic lurasidone hydrochloride landscape to highlight innovation and collaborations

The competitive landscape for generic lurasidone hydrochloride is characterized by a combination of global and regional players executing diverse strategies. Established generics houses leverage high-throughput manufacturing capabilities to achieve economies of scale, while emerging entrants differentiate through agile contract development and regulatory filing expertise. Alliances between API producers and formulation specialists optimize the balance between cost efficiency and product quality.

Innovation extends beyond traditional R&D efforts, encompassing digital adherence programs and patient assistance platforms that enhance real-world outcomes. Collaborative initiatives between manufacturers and clinical research organizations facilitate post-launch evidence generation, strengthening value propositions when negotiating with payers. In parallel, strategic acquisitions and joint ventures enable vertical integration, streamlining sourcing and distribution to safeguard margin integrity.

As competition intensifies, intellectual property vigilance and patent challenge strategies remain integral. By monitoring litigation trends and leveraging data exclusivity nuances, companies can time market entry to maximize impact while minimizing legal exposure. Altogether, these competitive maneuvers shape the evolving contours of the generic lurasidone hydrochloride market.

Providing actionable guidance to enhance regulatory compliance, drive market penetration, and inform investment strategies for generic lurasidone hydrochloride

To capitalize on emerging opportunities, manufacturers should strengthen regulatory intelligence capabilities, ensuring prompt alignment with evolving bioequivalence and manufacturing standards. Early engagement with health authorities can streamline submission pathways and reduce approval timelines. Parallel investments in quality management systems and supply chain traceability will safeguard against disruptions and reinforce credibility with payers and providers.

Enhancing market access requires the development of value-added services, such as patient support apps and adherence monitoring solutions that resonate with payers’ outcome-based objectives. Tailored pricing models, including outcome-linked contracts, can further differentiate generic offerings in highly price-sensitive markets. Collaborations with specialty pharmacies and digital health platforms will broaden channels and solidify brand equity among clinicians and patients.

Investment decisions should prioritize flexible manufacturing footprints that accommodate scale-up for high-volume strengths while enabling rapid transitions to new dosage formats. Scenario planning for tariff fluctuations and supply chain contingencies will mitigate margin erosion. By aligning corporate strategy with real-time market insights, industry leaders can navigate uncertainty and sustain growth in the competitive generics environment.

Detailing the comprehensive research methodology employed to ensure data integrity, analytical rigor, and robust insights into generic lurasidone hydrochloride

This analysis integrates primary and secondary research sources to deliver a holistic view of the generic lurasidone hydrochloride landscape. Primary research included structured interviews with regulatory experts, manufacturing operations leaders, and key decision-makers in distribution channels, yielding qualitative insights into approval processes, sourcing challenges, and adoption drivers. These interviews were complemented by facility visits to observe production workflows and quality assurance protocols.

Secondary research encompassed a comprehensive review of peer-reviewed journals, regulatory filings, patent databases, and public health agency reports. Cross-validation techniques ensured consistency between anecdotal and documented data points, while trend analysis illuminated shifts in policy and supply chain structures. A rigorous triangulation methodology reconciled disparate data sets, enhancing the robustness and reliability of the findings.

Quality assurance processes included peer reviews by subject matter experts and statistical validation of analytical models. Limitations were addressed by acknowledging data gaps in emerging markets and supplementing with expert assessments. This methodological framework underpins the strategic and operational recommendations presented herein, offering stakeholders confidence in the depth and integrity of the insights.

Concluding the strategic imperatives and essential takeaways from the generics landscape of lurasidone hydrochloride that inform future decision making

The generic lurasidone hydrochloride ecosystem is undergoing rapid transformation driven by patent expirations, regulatory streamlining, and evolving supply chain configurations. Recognizing the interplay between cost structures, regional policy environments, and clinical adoption patterns is essential for organizations seeking to establish or expand their footprint in this space.

Key takeaways underscore the importance of differentiated value propositions-ranging from rapid-dissolve formulations to integrated patient support tools-in an increasingly commoditized market. Regional nuances demand tailored strategies that reconcile global best practices with local regulatory and commercial realities. Meanwhile, proactive management of tariff and sourcing risks will serve as a competitive advantage as global economic conditions evolve.

By synthesizing these strategic imperatives, industry participants can chart clear pathways toward sustainable growth, operational excellence, and enhanced patient access to vital treatments in severe mood disorders.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Bipolar Depression
    • Major Depressive Disorder
    • Schizophrenia
  • Form
    • Orally Disintegrating Tablet
    • Tablet
  • Strength
    • 20 mg
    • 40 mg
    • 60 mg
    • 80 mg
  • Distribution Channel
    • Hospital Pharmacy
      • General Pharmacy
      • Psychiatric Unit
    • Online Pharmacy
      • Proprietary Platform
      • Third-Party Platform
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • End User
    • Clinics
      • Day Care Clinic
      • Outpatient Clinic
    • Home Care Settings
      • Caregiver Administration
      • Self-Administration
    • Hospitals
      • General Hospital
      • Psychiatric Facility
  • Packaging Type
    • Blister
    • Bottle
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Teva Pharmaceutical Industries Limited
  • Sandoz AG
  • Viatris Inc.
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Limited
  • Dr. Reddy's Laboratories Limited
  • Alembic Pharmaceuticals Limited
  • Lupin Limited
  • Cipla Limited
  • Macleods Pharmaceuticals Private Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of recent FDA tentative approvals on lurasidone hydrochloride generic market penetration
5.2. Emerging partnerships between generics manufacturers and contract research organizations for lurasidone trials
5.3. Adoption of digital adherence tools by generic lurasidone providers to improve patient compliance
5.4. Strategic pricing pressures from Indian and Chinese generic entrants in the lurasidone hydrochloride market
5.5. Development of extended release formulations to differentiate lurasidone hydrochloride generics in competitive markets
5.6. Influence of global supply chain disruptions on active pharmaceutical ingredient sourcing for lurasidone generics
5.7. Real-world evidence studies driving formulary inclusion of cost effective lurasidone hydrochloride generics
5.8. Impact of patent litigation outcomes on entry timing for first to file lurasidone hydrochloride generic applications
5.9. Role of biosimilar approval frameworks in shaping regulatory pathways for lurasidone hydrochloride generics
5.10. Growth opportunities in Latin America and Asia Pacific markets for low cost lurasidone hydrochloride generics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Lurasidone Hydrochloride Generics Market, by Application
8.1. Introduction
8.2. Bipolar Depression
8.3. Major Depressive Disorder
8.4. Schizophrenia
9. Lurasidone Hydrochloride Generics Market, by Form
9.1. Introduction
9.2. Orally Disintegrating Tablet
9.3. Tablet
10. Lurasidone Hydrochloride Generics Market, by Strength
10.1. Introduction
10.2. 20 mg
10.3. 40 mg
10.4. 60 mg
10.5. 80 mg
11. Lurasidone Hydrochloride Generics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. General Pharmacy
11.2.2. Psychiatric Unit
11.3. Online Pharmacy
11.3.1. Proprietary Platform
11.3.2. Third-Party Platform
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Lurasidone Hydrochloride Generics Market, by End User
12.1. Introduction
12.2. Clinics
12.2.1. Day Care Clinic
12.2.2. Outpatient Clinic
12.3. Home Care Settings
12.3.1. Caregiver Administration
12.3.2. Self-Administration
12.4. Hospitals
12.4.1. General Hospital
12.4.2. Psychiatric Facility
13. Lurasidone Hydrochloride Generics Market, by Packaging Type
13.1. Introduction
13.2. Blister
13.3. Bottle
14. Americas Lurasidone Hydrochloride Generics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Lurasidone Hydrochloride Generics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Lurasidone Hydrochloride Generics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Teva Pharmaceutical Industries Limited
17.3.2. Sandoz AG
17.3.3. Viatris Inc.
17.3.4. Aurobindo Pharma Limited
17.3.5. Sun Pharmaceutical Industries Limited
17.3.6. Dr. Reddy's Laboratories Limited
17.3.7. Alembic Pharmaceuticals Limited
17.3.8. Lupin Limited
17.3.9. Cipla Limited
17.3.10. Macleods Pharmaceuticals Private Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. LURASIDONE HYDROCHLORIDE GENERICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. LURASIDONE HYDROCHLORIDE GENERICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. LURASIDONE HYDROCHLORIDE GENERICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. LURASIDONE HYDROCHLORIDE GENERICS MARKET: RESEARCHAI
FIGURE 28. LURASIDONE HYDROCHLORIDE GENERICS MARKET: RESEARCHSTATISTICS
FIGURE 29. LURASIDONE HYDROCHLORIDE GENERICS MARKET: RESEARCHCONTACTS
FIGURE 30. LURASIDONE HYDROCHLORIDE GENERICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LURASIDONE HYDROCHLORIDE GENERICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BIPOLAR DEPRESSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BIPOLAR DEPRESSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ORALLY DISINTEGRATING TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ORALLY DISINTEGRATING TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 20 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 20 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 40 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 40 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 60 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 60 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 80 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 80 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY GENERAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY GENERAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PSYCHIATRIC UNIT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PSYCHIATRIC UNIT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PROPRIETARY PLATFORM, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PROPRIETARY PLATFORM, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY THIRD-PARTY PLATFORM, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY THIRD-PARTY PLATFORM, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DAY CARE CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DAY CARE CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY GENERAL HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY GENERAL HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PSYCHIATRIC FACILITY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PSYCHIATRIC FACILITY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BLISTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BLISTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BOTTLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BOTTLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 143. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 144. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 145. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 146. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 147. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 148. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 149. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 152. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 153. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 154. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 155. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 156. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 157. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 160. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 161. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 162. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 163. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 164. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 165. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 166. CANADA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 167. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 170. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 171. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 172. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 173. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 178. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 179. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 180. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 181. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 184. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 185. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 186. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 187. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 188. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 189. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 190. MEXICO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 289. GERMANY LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 290. GERMANY LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 291. GERMANY LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 292. GERMANY LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 293. GERMANY LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 294. GERMANY LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 29

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Lurasidone Hydrochloride Generics market report include:
  • Teva Pharmaceutical Industries Limited
  • Sandoz AG
  • Viatris Inc.
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Limited
  • Dr. Reddy's Laboratories Limited
  • Alembic Pharmaceuticals Limited
  • Lupin Limited
  • Cipla Limited
  • Macleods Pharmaceuticals Private Limited

Related Topics

Related Reports

United States and Japan LATUDA Market Drug Insight and Market Forecast - 2032 - Product Image

United States and Japan LATUDA Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • 30 Pages
  • Japan, United States Japan, United States
From
Schizophrenia Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Schizophrenia Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 397 Pages
  • Global
From
Lurasidone Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Image

Lurasidone Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 87 Pages
  • Global
From
Lurasidone (CAS 367514-87-2) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Lurasidone (CAS 367514-87-2) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
LATUDA Drug Insight and Market Forecast - 2032 - Product Image

LATUDA Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • 30 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.